{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:35Z","timestamp":1790746775094,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0585-5","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T14:35:16Z","timestamp":1521124516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-4840","authenticated-orcid":false,"given":"Hans Michael","family":"Kvasnicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"585_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000101708","volume":"74","author":"J Thiele","year":"2007","unstructured":"Thiele J, Kvasnicka HM. Myelofibrosis\u2014what\u2019s in a name? Consensus on definition and EUMNET grading. Pathobiology. 2007;74:89\u201396.","journal-title":"Pathobiology"},{"key":"585_CR2","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/ajh.24592","volume":"91","author":"A Tefferi","year":"2016","unstructured":"Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:1262\u201371.","journal-title":"Am J Hematol"},{"key":"585_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1055\/s-2006-942757","volume":"32","author":"HM Kvasnicka","year":"2006","unstructured":"Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362\u201371.","journal-title":"Semin Thromb Hemost"},{"key":"585_CR4","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1182\/blood-2007-09-112953","volume":"111","author":"C Vener","year":"2008","unstructured":"Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, Caberlon S, Gerli G, Boiocchi L, Deliliers GL. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111:1862\u20135.","journal-title":"Blood"},{"key":"585_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","volume":"25","author":"U Gianelli","year":"2012","unstructured":"Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, Savi F, Moro A, Grifoni F, De Philippis C, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25:1193\u2013202.","journal-title":"Mod Pathol"},{"key":"585_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","volume":"85","author":"J Thiele","year":"2006","unstructured":"Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings\u2014a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226\u201332.","journal-title":"Ann Hematol"},{"key":"585_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/1042819031000077070","volume":"44","author":"J Thiele","year":"2003","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma. 2003;44:949\u201353.","journal-title":"Leuk Lymphoma"},{"key":"585_CR8","doi-asserted-by":"crossref","unstructured":"Gianelli U, Fiori S, Cattaneo D, Bossi A, Cortinovis I, Bonometti A, Ercoli G, Bucelli C, Orofino N, Bulfamante G, Iurlo A. Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. Histopathology. 2017;","DOI":"10.1111\/his.13309"},{"key":"585_CR9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227\u201336.","journal-title":"Blood"},{"key":"585_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.24442","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91:918\u201322.","journal-title":"Am J Hematol"},{"key":"585_CR11","doi-asserted-by":"publisher","first-page":"E454","DOI":"10.1002\/ajh.24482","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Vannucchi AM. The prognostic impact of bone marrow fibrosis in primary myelofibrosis. Am J Hematol. 2016;91:E454\u20135.","journal-title":"Am J Hematol"},{"key":"585_CR12","doi-asserted-by":"crossref","unstructured":"Jeryczynski G, Thiele J, Gisslinger B, Wolfler A, Schalling M, Gleiss A, Burgstaller S, Buxhofer-Ausch V, Sliwa T, Schlogl E, et al. Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;","DOI":"10.1002\/ajh.24788"},{"key":"585_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"585_CR14","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"585_CR15","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","volume":"116","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116:2857\u20138.","journal-title":"Blood"},{"key":"585_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"585_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s12032-014-0869-8","volume":"31","author":"D Lekovic","year":"2014","unstructured":"Lekovic D, Gotic M, Perunicic-Jovanovic M, Vidovic A, Bogdanovic A, Jankovic G, Cokic V, Milic N. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol. 2014;31:869.","journal-title":"Med Oncol"},{"key":"585_CR18","doi-asserted-by":"crossref","unstructured":"Le Bousse-Kerdil\u00e8s MC: Primary myelofibrosis and the \u201cbad seeds in bad soil\u201d concept. Fibrogenesis Tissue Repair 2012, 5:S20.","DOI":"10.1186\/1755-1536-5-S1-S20"},{"key":"585_CR19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3324\/haematol.2015.141283","volume":"101","author":"AA Zahr","year":"2016","unstructured":"Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101:660\u201371.","journal-title":"Haematologica"},{"key":"585_CR20","first-page":"879","volume":"20","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A, Rathjen N, Metz KA, Beelen DW, Ditschkowski M, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol. 2005;20:879\u201389.","journal-title":"Histol Histopathol"},{"key":"585_CR21","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.exphem.2007.08.022","volume":"35","author":"N Kr\u00f6ger","year":"2007","unstructured":"Kr\u00f6ger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornh\u00e4user M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, on behalf of the MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol. 2007;35:1719\u201322.","journal-title":"Exp Hematol"},{"key":"585_CR22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1186\/1755-1536-5-S1-S25","volume":"5","author":"N Kr\u00f6ger","year":"2012","unstructured":"Kr\u00f6ger N, Kvasnicka M, Thiele J. Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair. 2012;5:S25.","journal-title":"Fibrogenesis Tissue Repair"},{"key":"585_CR23","unstructured":"Le Bousse-Kerdil\u00e8s MC, Martyr\u00e9 MC, Samson M: Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008, 19:69\u201380."},{"key":"585_CR24","doi-asserted-by":"crossref","unstructured":"Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdiles MC: Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediat Inflamm 2015, 2015:415024.","DOI":"10.1155\/2015\/415024"},{"key":"585_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/his.12871","volume":"68","author":"HM Kvasnicka","year":"2016","unstructured":"Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, Kremer M, Schmitt-Graeff A, Schwarz S, Thiele J, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis\u2014a consensus-based study. Histopathology. 2016;68:905\u201315.","journal-title":"Histopathology"},{"key":"585_CR26","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/modpathol.2014.69","volume":"27","author":"O Pozdnyakova","year":"2014","unstructured":"Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol. 2014;27:1447\u201354.","journal-title":"Mod Pathol"},{"key":"585_CR27","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica"},{"key":"585_CR28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.3109\/10428194.2013.769537","volume":"54","author":"A Nazha","year":"2013","unstructured":"Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013;54:2537\u20139.","journal-title":"Leuk Lymphoma"},{"key":"585_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/ehm.12.69","volume":"6","author":"RT Silver","year":"2013","unstructured":"Silver RT, Kiladjian J-J, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Exp Rev Hematol. 2013;6:49\u201358.","journal-title":"Exp Rev Hematol"},{"key":"585_CR30","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","volume":"117","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Goldman JJ. Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117:6669\u201372.","journal-title":"Blood"},{"key":"585_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","volume":"37","author":"T Stauffer Larsen","year":"2013","unstructured":"Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37:1041\u20135.","journal-title":"Leuk Res"},{"key":"585_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1365-2559.2003.01732.x","volume":"43","author":"J Thiele","year":"2003","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histopathology. 2003;43:470\u20139.","journal-title":"Histopathology"},{"key":"585_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"585_CR34","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120:1202\u20139.","journal-title":"Blood"},{"key":"585_CR35","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047\u201353.","journal-title":"Blood"},{"key":"585_CR36","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98:1865\u201371.","journal-title":"Haematologica"},{"key":"585_CR37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clml.2013.09.006","volume":"13","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis\u2014an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013;13:638\u201345.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"585_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12375","volume":"162","author":"CN Harrison","year":"2013","unstructured":"Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162:229\u201339.","journal-title":"Br J Haematol"},{"key":"585_CR39","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31:1285\u201392.","journal-title":"J Clin Oncol"},{"key":"585_CR40","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, Vannucchi A, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123:1833\u201355.","journal-title":"Blood"},{"key":"585_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.","journal-title":"J Hematol Oncol"},{"key":"585_CR42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701\u20137.","journal-title":"Leukemia"},{"key":"585_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-015-0644-4","volume":"13","author":"C Jamieson","year":"2015","unstructured":"Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015;13:294.","journal-title":"J Transl Med"},{"key":"585_CR44","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","volume":"98","author":"BS Wilkins","year":"2013","unstructured":"Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98:1872\u20136.","journal-title":"Haematologica"},{"key":"585_CR45","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00277-015-2429-5","volume":"94","author":"A Iurlo","year":"2015","unstructured":"Iurlo A, Cattaneo D, Boiocchi L, Orofino N, Fermo E, Cortelezzi A, Gianelli U. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. Ann Hematol. 2015;94:1749\u201351.","journal-title":"Ann Hematol"},{"key":"585_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/17474086.2017.1273766","volume":"10","author":"F Massaro","year":"2017","unstructured":"Massaro F, Molica M, Breccia M. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. Expert Rev Hematol. 2017;10:155\u20139.","journal-title":"Expert Rev Hematol"},{"key":"585_CR47","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117\u201327.","journal-title":"N Engl J Med"},{"key":"585_CR48","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013\u20138.","journal-title":"Blood"},{"key":"585_CR49","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"585_CR50","first-page":"633","volume":"20","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features\u2014does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol. 2005;20:633\u201344.","journal-title":"Histol Histopathol"},{"key":"585_CR51","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood"},{"key":"585_CR52","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","volume":"30","author":"F Cervantes","year":"2012","unstructured":"Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, Demory JL, Rumi E, Guglielmelli P, Roncoroni E, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30:2981\u20137.","journal-title":"J Clin Oncol"},{"key":"585_CR53","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1182\/blood-2013-02-481788","volume":"122","author":"CHM Jamieson","year":"2013","unstructured":"Jamieson CHM, Hasserjian RP, Gotlib J, Cortes JE, Stone RM, Talpaz M, Thiele J, Rodig SJ, Patki A, Wu K, et al. Effect of treatment with the JAK2-selective inhibitor fedratinib (SAR302503) on bone marrow histology in patients with myeloproliferative neoplasms with myelofibrosis [abstract]. Blood. 2013;122:2823.","journal-title":"Blood"},{"key":"585_CR54","doi-asserted-by":"crossref","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, Cortes JE, Kantarjian HM, Verstovsek S: Effects of ruxolitinib therapy on megakaryocyte morphology and inflammatory bone marrow reaction in patients with myelofibrosis [abstract]. Blood 2013, 122:4056.","DOI":"10.1182\/blood.V122.21.4056.4056"},{"key":"585_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","volume":"139","author":"DJ Kuter","year":"2007","unstructured":"Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351\u201362.","journal-title":"Br J Haematol"},{"key":"585_CR56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0344-0338(85)80142-4","volume":"179","author":"J Thiele","year":"1985","unstructured":"Thiele J, Laubert A, Vykoupil KF, Georgii A. Autopsy and clinical findings in acute leukemia and chronic myeloproliferative diseases\u2014an evaluation of 104 patients. Pathol Res Pract. 1985;179:328\u201336.","journal-title":"Pathol Res Pract"},{"key":"585_CR57","doi-asserted-by":"crossref","unstructured":"Pozdnyakova O, Rodig S, Bhandarkar S, Wu K, Thiele J, Hasserjian R. The importance of central pathology review in international trials: a comparison of local vs. central bone marrow reticulin grading. Leukemia. 2014;","DOI":"10.1038\/leu.2014.262"},{"key":"585_CR58","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.leukres.2010.01.005","volume":"34","author":"CJ Teman","year":"2010","unstructured":"Teman CJ, Wilson AR, Perkins SL, Hickman K, Prchal JT, Salama ME. Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study. Leuk Res. 2010;34:871\u20136.","journal-title":"Leuk Res"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0585-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0585-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0585-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T09:53:45Z","timestamp":1603965225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0585-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0585-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"12 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the International Conference on Harmonization guidelines for Good Clinical Practice. The clinical study protocol was approved by the MDACC Institutional Review Board and for the BAT group by the University of Frankfurt Ethics Committee (UCT project number SHN-07-2016). Details of the INCB18424-251 study design (identifier NCT00509899) have been previously published []. All patients provided written informed consent in accordance with the Declaration of Helsinki prior to study participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.M.K. reports receiving consulting or advisory fees from Incyte Corporation, AOP Orphan Pharmaceuticals, and Novartis; honoraria from Incyte Corporation and Novartis; research funding from AOP Orphan Pharmaceuticals and Novartis; and other remunerations from Incyte Corporation and Novartis. J.T. reports receiving consulting or advisory fees from Incyte Corporation, AOP Orphan Pharmaceuticals, Novartis, and Sanofi; honoraria from Incyte Corporation, Novartis, and Sanofi; research funding from Incyte Corporation, AOP Orphan Pharmaceuticals, Novartis, and Shire; and other remunerations from Incyte Corporation, Novartis, and Sanofi. C.E.B-R reports receiving consulting or advisory fees from Incyte Corporation and honoraria from Novartis. W.S. is an employee of and holds stock in Incyte Corporation. J.C. reports receiving consulting or advisory fees from Incyte Corporation and Sanofi and receiving research funding from Incyte Corporation and Sanofi. H.M.K. reports receiving research funding from ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. S.V. reports receiving research funding from Incyte Corporation, AstraZeneca, Lilly Oncology, Geron, NS Pharma, Bristol-Myers Squibb, Novartis, Celgene, Gilead, Seattle Genetics, Promedior, and Cell Therapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"42"}}